Venus Remedies Receives 'Hold' Rating, Shows Strong Growth

Venus Remedies, a microcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO on November 6, 2023. This upgrade is based on the company's strong ability to service its debt, with a healthy EBIT to Interest ratio of 11.70. Additionally, the company has shown a healthy long-term growth rate, with an annual operating profit growth rate of 115.00%.
In terms of financials, Venus Remedies has also shown impressive growth, with its PBT LESS OI(Q) growing at 183.67% and its PAT(Q) growing at 86.5%. The company also has a strong cash position, with CASH AND CASH EQUIVALENTS(HY) at its highest at Rs 67.68 crore.

From a technical standpoint, the stock is currently in a bullish range and has shown a significant improvement since November 7, 2023, generating a return of 42.19%. Multiple technical indicators, such as MACD, Bollinger Band, KST, and OBV, also suggest a bullish trend for the stock.

With a ROE of 5.4, Venus Remedies is currently fairly valued with a price to book value of 1.1. However, the stock is trading at a premium compared to its historical valuations. Despite this, the company has shown strong market-beating performance in both the long-term and near-term, with a return of 105.14% in the last year and outperforming BSE 500 in the last 3 years, 1 year, and 3 months.

It is worth noting that despite its small size, domestic mutual funds hold only 0% of the company. This could signify that they are either not comfortable with the current price or have not conducted in-depth research on the company. Nevertheless, Venus Remedies has shown promising growth and performance, making it a stock to watch in the pharmaceutical industry.